Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 403.56 Million USD | -0.01% |
| 2021 | 407.91 Million USD | 76.15% |
| 2020 | 231.57 Million USD | 8.02% |
| 2019 | 214.37 Million USD | 52.47% |
| 2018 | 140.6 Million USD | 58.88% |
| 2017 | 88.49 Million USD | 37.51% |
| 2016 | 64.35 Million USD | 22.27% |
| 2015 | 52.63 Million USD | 44.93% |
| 2014 | 36.31 Million USD | 125.03% |
| 2013 | 16.13 Million USD | 196.85% |
| 2012 | 5.43 Million USD | 44.14% |
| 2011 | 3.77 Million USD | 51.18% |
| 2010 | 2.49 Million USD | 161.47% |
| 2009 | 954.12 Thousand USD | 400.81% |
| 2008 | 190.51 Thousand USD | -20.83% |
| 2007 | 240.63 Thousand USD | -45.22% |
| 2006 | 439.28 Thousand USD | 242.61% |
| 2005 | -308.03 Thousand USD | -40271.04% |
| 2004 | -763.00 USD | 0.0% |
| 2003 | -763.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 99.91 Million USD | 22.39% |
| 2023 Q2 | 83.33 Million USD | -16.59% |
| 2022 Q4 | 81.63 Million USD | -31.56% |
| 2022 Q3 | 119.27 Million USD | 22.16% |
| 2022 FY | 407.88 Million USD | -0.01% |
| 2022 Q2 | 97.63 Million USD | -10.7% |
| 2022 Q1 | 109.33 Million USD | -3.85% |
| 2021 Q1 | 88.26 Million USD | 15.8% |
| 2021 Q2 | 105.96 Million USD | 20.06% |
| 2021 Q3 | 95.88 Million USD | -9.52% |
| 2021 Q4 | 113.71 Million USD | 18.6% |
| 2021 FY | 407.91 Million USD | 76.15% |
| 2020 Q3 | 57.3 Million USD | 15.52% |
| 2020 FY | 231.57 Million USD | 8.02% |
| 2020 Q2 | 49.6 Million USD | 2.39% |
| 2020 Q1 | 48.44 Million USD | -12.53% |
| 2020 Q4 | 76.22 Million USD | 33.01% |
| 2019 Q2 | 53.52 Million USD | 3.58% |
| 2019 Q4 | 55.38 Million USD | 2.95% |
| 2019 FY | 214.37 Million USD | 52.47% |
| 2019 Q1 | 51.67 Million USD | 6.74% |
| 2019 Q3 | 53.79 Million USD | 0.51% |
| 2018 Q2 | 29.62 Million USD | 17.29% |
| 2018 Q4 | 48.41 Million USD | 20.05% |
| 2018 FY | 140.6 Million USD | 58.88% |
| 2018 Q1 | 25.25 Million USD | 22.21% |
| 2018 Q3 | 40.32 Million USD | 36.13% |
| 2017 Q3 | 27.47 Million USD | 31.23% |
| 2017 Q1 | 27.39 Million USD | 12.73% |
| 2017 FY | 88.49 Million USD | 37.51% |
| 2017 Q4 | 20.66 Million USD | -24.78% |
| 2017 Q2 | 20.93 Million USD | -23.58% |
| 2016 FY | 64.35 Million USD | 22.27% |
| 2016 Q2 | 14.96 Million USD | 20.83% |
| 2016 Q1 | 12.38 Million USD | -33.17% |
| 2016 Q3 | 15.59 Million USD | 4.2% |
| 2016 Q4 | 24.3 Million USD | 55.88% |
| 2015 Q2 | 11.39 Million USD | 7.02% |
| 2015 FY | 52.63 Million USD | 44.93% |
| 2015 Q3 | 12.06 Million USD | 5.92% |
| 2015 Q4 | 18.52 Million USD | 53.56% |
| 2015 Q1 | 10.64 Million USD | 5.39% |
| 2014 Q1 | 10.07 Million USD | 56.24% |
| 2014 FY | 36.31 Million USD | 125.03% |
| 2014 Q3 | 7.88 Million USD | -4.55% |
| 2014 Q2 | 8.25 Million USD | -18.08% |
| 2014 Q4 | 10.1 Million USD | 28.19% |
| 2013 Q3 | 3.39 Million USD | -7.07% |
| 2013 FY | 16.13 Million USD | 196.85% |
| 2013 Q1 | 2.64 Million USD | 40.96% |
| 2013 Q4 | 6.45 Million USD | 90.24% |
| 2013 Q2 | 3.64 Million USD | 37.77% |
| 2012 Q3 | 1.37 Million USD | 18.58% |
| 2012 FY | 5.43 Million USD | 44.14% |
| 2012 Q2 | 1.16 Million USD | 14.17% |
| 2012 Q1 | 1.01 Million USD | 14.2% |
| 2012 Q4 | 1.87 Million USD | 36.36% |
| 2011 Q1 | 921.45 Thousand USD | 31.54% |
| 2011 Q3 | 795.42 Thousand USD | -31.64% |
| 2011 FY | 3.77 Million USD | 51.18% |
| 2011 Q2 | 1.16 Million USD | 26.27% |
| 2011 Q4 | 891.22 Thousand USD | 12.04% |
| 2010 Q4 | 700.51 Thousand USD | 25.12% |
| 2010 Q1 | 601.39 Thousand USD | -12.93% |
| 2010 Q2 | 632.95 Thousand USD | 5.25% |
| 2010 Q3 | 559.87 Thousand USD | -11.55% |
| 2010 FY | 2.49 Million USD | 161.47% |
| 2009 Q3 | 238.66 Thousand USD | 199.16% |
| 2009 Q1 | 58.83 Thousand USD | 27.69% |
| 2009 FY | 954.12 Thousand USD | 400.81% |
| 2009 Q4 | 690.68 Thousand USD | 189.39% |
| 2009 Q2 | 79.77 Thousand USD | 35.59% |
| 2008 Q3 | 125.84 Thousand USD | 2215.83% |
| 2008 Q4 | 46.07 Thousand USD | -63.38% |
| 2008 Q2 | 5434.00 USD | -58.71% |
| 2008 Q1 | 13.16 Thousand USD | 77.41% |
| 2008 FY | 190.51 Thousand USD | -20.83% |
| 2007 Q3 | 10.64 Thousand USD | -15.64% |
| 2007 Q1 | 209.94 Thousand USD | 0.0% |
| 2007 FY | 240.63 Thousand USD | -45.22% |
| 2007 Q4 | 7418.00 USD | -30.32% |
| 2007 Q2 | 12.62 Thousand USD | -93.99% |
| 2006 FY | 439.28 Thousand USD | 242.61% |
| 2006 Q1 | - USD | 100.0% |
| 2005 Q3 | -191.00 USD | 0.0% |
| 2005 Q1 | -191.00 USD | -0.53% |
| 2005 FY | -308.03 Thousand USD | -40271.04% |
| 2005 Q4 | -307.45 Thousand USD | -160872.77% |
| 2005 Q2 | -191.00 USD | 0.0% |
| 2004 FY | -763.00 USD | 0.0% |
| 2004 Q2 | -191.00 USD | 0.0% |
| 2004 Q1 | -191.00 USD | 0.0% |
| 2004 Q3 | -191.00 USD | 0.0% |
| 2004 Q4 | -190.00 USD | 0.52% |
| 2003 FY | -763.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -60931.983% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -4254.37% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1245.524% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -501.014% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2447.264% |
| Better Therapeutics, Inc. | 38.26 Million USD | -954.736% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -891.823% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -3156.45% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1092.421% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1072.501% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -272.064% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -40548.604% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1138.341% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -759.541% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -33123.593% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1923.958% |
| Molecular Templates, Inc. | 63.09 Million USD | -539.652% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -2796.746% |
| NexImmune, Inc. | 28.16 Million USD | -1332.725% |
| Orgenesis Inc. | 45.75 Million USD | -781.97% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1473.529% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -549593.527% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2399.574% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3344.876% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1299.826% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2031.983% |
| Trevena, Inc. | 38.41 Million USD | -950.59% |
| Vaxxinity, Inc. | 56.05 Million USD | -619.993% |
| Vaccinex, Inc. | 23.45 Million USD | -1620.584% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -38445.509% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -696.092% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -5447.546% |